OBJECTIVE: This study aimed to analyze the relationship of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and monocyte-lymphocyte ratio (MLR) with clinicopathological characteristics of patients with differentiated thyroid cancer (DTC). METHODS: This retrospective study included 390 patients with DTC who had complete blood cell counts available at the time of surgery. NLR, PLR, and MLR were calculated, and the risk of cancer-related death, structural recurrence, and response to therapy were assessed using the eighth edition of the tumor-node-metastasis classification, American Thyroid Association (ATA) Risk Stratification System, and ATA Response to Therapy Reclassification, respectively. RESULTS: PLR was higher in patients with distant metastasis than in those without (133.15±43.95 versus 119.24±45.69, p=0.0345) and lower in patients with disease-free status (117.72±44.70 versus 131.07±47.85, p=0.0089) than in those who experienced persistent disease or death. Patients aged ≥55 years had a higher MLR than those aged <55 years (0.26±0.10 versus 0.24±0.12, p=0.0379). Higher MLR (odds ratio [OR]: 8.775, 95% confidence interval [CI]: 1.532-50.273, p=0.0147), intermediate ATA risk (OR: 4.892, 95% CI: 2.492-9.605, p≤0.0001), and high ATA risk (OR: 5.998, 95% CI: 3.126-11.505, p≤0.0001) were risk factors associated with active disease. NLR was not significantly different among the studied variables. Receiver operating characteristic curve cut-off values for NLR, PLR, and MLR were able to differentiate distant metastasis from lymph node metastasis (NLR>1.93: 73.3% sensitivity and 58.7% specificity, PLR>124.34: 86.7% sensitivity and 69.2% specificity, MLR>0.21: 80% sensitivity and 45.2% specificity). CONCLUSION: Cut-off values of NLR, PLR, and MLR differentiated distant metastasis from lymph node metastasis with good sensitivity and accuracy. PLR was associated with disease-free status and it was higher in DTC patients with distant metastasis, persistent disease, and disease-related death. MLR was a risk factor for active disease.

OBJETIVO: Avaliar o impacto do tempo de hipoglicemia silenciosa no controle glicêmico de pacientes diabéticos tipo 1 (DM1) sob monitorização contínua de glicose (CGMS). MÉTODOS: Oitenta e sete pacientes DM1 (45%M/55%F), divididos em quatro grupos, submetidos à CGMS 72 horas. Foram analisados: hipoglicemia silenciosa (HS) (< 70 mg/dL); tempo de hipoglicemia pelo CGMS, sendo os pacientes classificados em G1 (< 5%), G2 (5-10%), G3 (10% a 20%) e G4 (> 20%); níveis de A1c e médias glicêmicas. RESULTADOS: A HS foi detectada em 64,5% dos casos, sendo mais duradoura (mín.) durante a noite versus o dia (p < 0,001). Quanto ao tempo de HS, 41,4% dos pacientes ficaram < 5%, 21,8% entre 5% a 10%, 23% entre 10% a 20% e 13,8% com > 20% do CGMS 72 horas. Verificou-se menor média glicêmica quanto maior o tempo de hipoglicemia (p = 0,006). CONCLUSÃO: A hipoglicemia silenciosa é freqüente em pacientes com DM1, no período noturno. Observou-se tempo de 10% a 20% de hipoglicemia silenciosa para a média glicêmica entre 120 a 160 mg/dL.

BACKGROUND: To evaluate the impact of silent hypoglycemic state in glycemic control in type 1 diabetic patients (DM1) by CGMS. METHODS: 87 DM1 patients (45%M/55%F) submitted to a 72h CGMS profile were classified in 4 groups. It was analyzed: unrecognized hypoglycemia (<70mg/dL); duration time of silent hypoglycemia in which patients were classified into G1 (<5%), G2 (5-10%), G3 (10-20%) and G4 (>20%) of hypoglycemic state by CGMS; A1c and mean capillary glucose (MCG) in each group. RESULTS: The silent hypoglycemia was detected in 64.5% of patients and nighttime episodes of hypoglycemia lasted longer (min) than daytime episodes in all groups (p<0.001). It was verified 41.4% of patients under than 5% of time in hypoglycemic state, 21.8% between 5-10%, 23% between 10-20% and 13.8% with more than 20% of CGMS in silent hypoglycemia. This data showed significant decreased in MCG when the duration time of silent hypoglycemia was longer (p=0.006). CONCLUSION: The silent hypoglycemia is common in DM1 patients and most frequently in night time period. To take an average glycemia of 120-160mg/dL in these patients, it was necessary a 10-20% of CGMS period in silent hypoglycemia in these patients.

O uso prolongado dos inibidores da bomba de prótons tem sido considerado uma condição de risco para o desenvolvimento de gastrite atrófica e tumores gástricos. Objetivo: Estudar o efeito do uso de pantoprazol (PTZ) e carcinogênese pela "N-Nitroso-N-Methylurea" (NMU), por 15 semanas, sobre o estômago glandular de ratos Wistar, pela análise histológica e computadorizada das áreas com células parietais (AP), principais (AZ) e da mucosa não oxíntica (ANO), além do estudo das alterações histopatológicas identificadas. Métodos: Quarenta ratos Wistar machos foram distribuídos em 4 grupos: G1 (controle), G2 (NMU+PTZ), G3 (PTZ) e G4 (NMU). O pantoprazol foi administrado 2x/semana (14mg/kg de peso, i.p.) e a NMU oferecida, ad libitum, diluída na água de beber (100mig/ml). Após o estudo histológico AP, AZ e ANO foram determinadas por análise computadorizada das imagens dos estômagos, utilizando o programa "ImageJ 1.19z". Resultados: Mostraram redução da AP e aumento da ANO, em G2, G3 e G4 (p<0,001). Foram encontrados casos de atrofia, inflamação aguda e inflamação crônica, em número que impediu comparação estatística entre os grupos estudados. Conclusão: O uso contínuo de pantoprazol (i.p.), por 15 semanas, reduziu a área com células parietais e aumentou a área de mucosa não oxíntica no estômago glandular de ratos Wistar machos. O mesmo aconteceu no grupo de animais que receberam NMU isoladamente ou em associação com o pantoprazol.

The long-term use of proton bomb inhibitors has been considered a risk condition for the development of atrophic gastritis and gastric tumors. Objective: The aim of this study was to investigate the effects of pantoprazole (PTZ) treatment and N-Nitroso-N-Methylurea (NMU) carcinogenesis, for 15 weeks, in the glandular stomach of rats by histological and computer-assisted analysis of parietal cells area (PA), chief cells area (CP) and non-oxintic mucosal area (ANO), as well as by histopathological study. Methods: A total of 40 male Wistar rats were divided into four groups on the basis of the treatment: G1 (control), G2 (NMU+PTZ), G3 (PTZ) and G4 (NMU). Pantoprazole was administered twice a week (14mg/kg body wt., i.p.) and NMU was given in the drinking water (100ppm) ad libitum. After histological examination AP, AZ and ANO were investigated by computer-assisted analysis of the stomach image using the program ImageJ1.19z. Results: Showed a reduction of AP and increase of ANO in G2, G3 and G4 (p<0,001). Cases of atrophy, acute and chronic inflammation were found in number that impeded statistical comparison among the studied groups. Conclusion: The continuous administration, for 15 weeks, of pantoprazole (14mg/kg body wt., i.p.) and NMU (100ppm in the drinking water, ad libitum), isolated or associated, determines a reduction of parietal cells area and increase of non-oxintic mucosal area in glandular stomach of male Wistar rats.